Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use
- 19 January 2021
- journal article
- letter
- Published by Elsevier BV in Annales de Dermatologie et de Vénéréologie
- Vol. 148 (2), 140-141
- https://doi.org/10.1016/j.annder.2020.10.018
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Nonmelanoma skin cancer associated with Hydroxyurea treatment: Overview of the literature and our own experienceDermatologic Therapy, 2019
- Development of Aggressive Squamous Cell Carcinoma With Perineural Invasion During Ruxolitinib TreatmentDermatologic Surgery, 2019
- The role of JAK2 inhibitors in MPNs 7 years after approvalBlood, 2018
- Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinibJAAD Case Reports, 2018
- Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with ruxolitinibBritish Journal of Dermatology, 2015
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibitionNature Medicine, 2014
- Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: Implications for treatment modality selectionJournal of the American Academy of Dermatology, 1992